{"ticker": {"uuid": "ba66de50-b4c5-4885-b13b-b8302704ca4b", "symbol": "VKTX", "name": "Viking Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026", "summary": "Viking Therapeutics, Inc. (NASDAQ: VKTX) announced it will release its second-quarter 2026 financial results after the market closes on Wednesday, July 29, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and provide", "url": "https://au.finance.yahoo.com/news/viking-therapeutics-report-financial-results-200500197.html", "source_name": "Market source", "published_at": "2026-07-22T20:10:58", "published_display": "22 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics\u2019 Q2 results arrive after markets close", "summary": "Viking Therapeutics (NASDAQ: VKTX) is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will also host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and provide corporate", "url": "https://www.stocktitan.net/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-d0empr90iawt.html", "source_name": "Stock Titan", "published_at": "2026-07-22T20:10:58", "published_display": "22 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYmtFNjdGWXBNbkxfbGpBYW53RXhvSlRkb3FoVG5KazFjWEY4RWZuMjVtYWtWWjdmTmNhSHBrSGZmTi01S3R1QWVOWmU3Y2xuVk52bEtJSDZiWlQ2TXFBYy1qRlhJV3JScmtaMzR6aldMbXdGdmNMdEVfTmNTVkx6ZGJQeEZ3c2JwV1llVTEzb2lBOHpwUkFXczZ6RFh3ZW5JeTdaMUVmajIyWHhCbmlnRmQxbmFqdGljOWlVTDN5aE85RlE2b0o3Nw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-22T12:02:35+00:00", "published_display": "22 Jul 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term VKTX stockholders to contact them for a free and no-obliga", "url": "https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-viking-therapeutics-inc-to-contact-law-firm-302831251.html", "source_name": "PR Newswire", "published_at": "2026-07-21T20:40:19", "published_display": "21 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1", "summary": "", "url": "https://finance.yahoo.com/m/3ee1a5bf-2109-3c8d-86ea-ce77ff0c9422/watch-out%2C-eli-lilly-and-novo.html", "source_name": "Motley Fool", "published_at": "2026-07-18T20:05:00+00:00", "published_display": "18 Jul 2026 20:05", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOUEJPM1dEMWYyR2ZtU2ViMThySUUwdFc3ZFNkWUE5NDBlR0ZWUXluREFpeEJvbVptc0NldWkzbWhRLTVMMmc0dnJzbVBYWFJmU3A1dnp5TWdveHJWMG9sQUJUNTZRMXNRRUk2N05CYVRKQU45WFM3UTNaSm5NaWdDVkpUODZqVjg0dUNVY1huR3Z3VEpkZmR3ZjlsTmRsZGd6VzZGSDdhblhUbTQzOVdpRzdLelk?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-18T17:04:16+00:00", "published_display": "18 Jul 2026 17:04", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming \"Yes.\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNcGp3YnNOREN0LXZQdXY3VXFMeDZwQ19NRVNZandoSWo5RnZya0hHN214QkVyaXgzUEtqcmJEVXQtaG1RRWsyM1owSzA5V0lDYW9rUUt5c1liYWVyd1Y2UEg3dUw5a3hhdUE3VzFwTklaNm5ZNDJpb0E1dDZRNGt5MDVabnpUWDdNV2hsMUdYbXFvdk9zMWJvZGtNVXU1V1U?oc=5", "source_name": "Market source", "published_at": "2026-07-18T13:50:00+00:00", "published_display": "18 Jul 2026 13:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?", "summary": "Viking Therapeutics (VKTX) is set to report its second-quarter 2026 earnings, with investors keenly focused on pipeline updates, particularly for its lead candidate VK2735 for obesity treatment. The company has no marketed drugs, so no revenues are expected, and analysts forecast", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/3338112/viking-therapeutics-to-report-q2-earnings-whats-in-store-for-the-stock/", "source_name": "The Globe and Mail", "published_at": "2026-07-18T01:10:33", "published_display": "18 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note", "summary": "Viking Therapeutics (VKTX) stock performed strongly, gaining 1.95% while the broader market indices like the S&P 500, Dow, and Nasdaq fell. The company's stock has risen 19.72% over the past month, outperforming its sector and the S&P 500. Analysts expect Viking Therapeutics to r", "url": "https://sg.finance.yahoo.com/news/viking-therapeutics-inc-vktx-ascends-214505745.html", "source_name": "Market source", "published_at": "2026-07-17T22:09:09", "published_display": "17 Jul 2026 22:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial", "summary": "Viking Therapeutics (VKTX) has initiated a Phase 1 study for VK3019, a potential weight loss therapy. Despite recent stock fluctuations, the company shows strong long-term momentum, with Simply Wall St's analysis suggesting it is 61% undervalued compared to a fair value of $92.72", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-could-be-61-undervalued-as-it-start", "source_name": "Simply Wall Street", "published_at": "2026-07-17T20:09:09", "published_display": "17 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Law firm probes Viking Therapeutics officers for possible self-dealing harming shareholders", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties through potential self-dealing, which could result in shareholder damages. The firm is encouraging long-term shareholders to contact them for free consulta", "url": "https://pluang.com/en/news-feed/kuehn-law-ajakan-pemegang-saham-viking-therapeutics-untuk-kontak-firma-hukum", "source_name": "Pluang", "published_at": "2026-07-17T01:40:46", "published_display": "17 Jul 2026 01:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQZTRaelZOYV9TaDhlai1IX0VsWE1ZNEc5NHo5RkJRSnFCVmJ1TTlONXJsY3pSYkI5SjR3eWhDVUJ6TXdvdUVSRUlSdng3cDdxWW11ZExSbGZUU0JjME1RMWZYTlQ4QmhlR2d0ZFE4eDljOVEzWG5FRjVoRzA1WmNOX3BXeE1ESFN2R3BVNkUzY3dBR2hMUkpKcUpTNzRqUU9V?oc=5", "source_name": "Market source", "published_at": "2026-07-16T21:50:04+00:00", "published_display": "16 Jul 2026 21:50", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here Is Why Viking Therapeutics (VKTX) is Amongst The Most Affordable Biotech Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNd1FSMHQyaXBELUNScW1CVlR3LXlKNERyOTRkaWNUREZTekY2S3ZUY2lrNTJBVXlacWE4LUtkYUlPUHEtVVZfYW9kWFdTTjFvdExyUzdyaE01eTY2X2V5RmZUQjZwUEJ4dnZMc0lzOHFDZ2pTWFdoMjQ0Q2ZpVFZCY1kwNWcwemF4ZktJQTVLOU02ZGtEb09jVWxpa2w4dw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:42+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival", "summary": "Viking Therapeutics' new obesity drug candidate, VK3019, demonstrated stronger early weight-loss signals in animal studies compared to Novo Nordisk's amylin therapy, although VKTX stock dipped slightly after the announcement. The company plans to begin Phase 1 testing for VK3019 ", "url": "https://stocktwits.com/news-articles/markets/equity/vktx-stock-slips-premarket-obesity-drug-beats-novo-animal-tests/cZBM2E4Re4b", "source_name": "Stocktwits", "published_at": "2026-07-11T04:43:25", "published_display": "11 Jul 2026 04:43", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "Viking Therapeutics (VKTX) stock fell 5.54% in the latest trading session, underperforming the broader market which saw gains. Despite this dip, the company's shares have increased significantly over the last month. Investors are anticipating VKTX's upcoming financial results, wi", "url": "https://ca.finance.yahoo.com/news/viking-therapeutics-inc-vktx-stock-214503928.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-10T21:40:16", "published_display": "10 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years", "summary": "Viking Therapeutics (NASDAQ: VKTX) has significantly outperformed the market over the last decade, with an annualized return of 40.15%. An initial investment of $1000 in VKTX stock ten years ago would now be worth $29,903.10. This impressive performance highlights the power of co", "url": "https://www.benzinga.com/news/26/07/60392425/here-s-how-much-you-would-have-made-owning-viking-therapeutics-stock-last-10-years", "source_name": "Benzinga", "published_at": "2026-07-10T16:39:19", "published_display": "10 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength", "summary": "Viking Therapeutics (VKTX) is showing signs of a long-term bottoming pattern, with improving technical indicators suggesting a potential breakout. Key resistance is at $43.15, and recent advances with increased volume signal strengthening demand. While a pullback could precede a ", "url": "https://www.fxempire.com/forecasts/article/viking-therapeutics-vktx-price-forecast-bottoming-pattern-signals-growing-strength-1609462", "source_name": "FXEmpire", "published_at": "2026-07-09T21:33:57", "published_display": "09 Jul 2026 21:33", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?", "summary": "Viking Therapeutics has expanded its obesity drug pipeline by initiating a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist, alongside its existing GLP-1/GIP program. While VK3019 broadens the company's multi-mechanism approach to obesity treatment, the nea", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/does-viking-therapeutics-vktx-expanding-into-dual-agonist-ob", "source_name": "Simply Wall Street", "published_at": "2026-07-09T21:03:57", "published_display": "09 Jul 2026 21:03", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?", "summary": "Viking Therapeutics (VKTX) is increasingly seen as a potential acquisition target due to its expanding obesity franchise, particularly with its lead candidate VK2735 and the addition of VK3019. The company is poised for a significant catalyst with upcoming data readouts from a ma", "url": "https://www.tradingview.com/news/zacks:6d7d003ca094b:0-buyout-buzz-around-vktx-is-back-what-s-fueling-the-speculation/", "source_name": "TradingView", "published_at": "2026-07-09T14:03:57", "published_display": "09 Jul 2026 14:03", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Jefferies Global Healthcare Conference 2026 Summary", "summary": "This summary from the Jefferies Global Healthcare Conference 2026 details Viking Therapeutics' progress, including two Phase III trials for obesity (VANQUISH-1 and VANQUISH-2) nearing data release in late 2027, and the impending launch of two Phase III trials for an oral GLP-1/GI", "url": "https://quartr.com/events/viking-therapeutics-vktx-jefferies-global-healthcare-conference-2026_on2AF4xJ", "source_name": "Quartr", "published_at": "2026-07-08T22:43:25", "published_display": "08 Jul 2026 22:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Stock Looks Pricey After New Obesity Trial Launch", "summary": "Viking Therapeutics' stock appears expensive due to a high P/B ratio compared to industry averages, despite a strong five-year return. The launch of its Phase 1 obesity trial for VK3019 supports a broader pipeline, but clinical and regulatory risks persist. The company's valuatio", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-stock-looks-pricey-after-new-obesit/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T11:39:53", "published_display": "08 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPczZPMWFhaHU3Q3FaMGxMWU5HVGxlV3d1eDNmYklhMWpfdWJId00wbnBJR0lwS2F0VkxYb1Bod1hUMDh0MEVjRURrVmF3NWE0cGVZY1pEbElaV0VZU0Z4dWg1R1VUZ3dtanNPRDBJQTZ2UjJpSXlMOUw2WXRBUzBGbjRIMWJUbk1SMnkydnBoNEI0eEZ2UlJFRWhBRG5kTC1kY0dJ?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Could Be 120% Undervalued On Obesity Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxONTg2c2xDWm1HeThZZ1dTamRXbGNSZ3NRMm94X1hQcVB5RkMzV0l2bHJDcldCS1AtX0t0ZHNBSTBVb2ZVa0hYZXcxU2J4Y3FiQTNqeHNtR202bThPU0JwcTdwb2YyRFUxTjRjSmMyVnZjQ3hvMUFpYVBRY0NfNHE2bXhuVmVIVXBfYml4RkNPdWZPT3k4czY1OXF6SQ?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 \u2013 And What's Next", "summary": "Viking Therapeutics has initiated a Phase 1 trial for its new obesity drug VK3019, a dual amylin and calcitonin receptor agonist, broadening its metabolic pipeline alongside its advanced VK2735 program. This development could reshape Viking's investment narrative by adding anothe", "url": "https://finance.yahoo.com/healthcare/articles/why-viking-therapeutics-vktx-8-061220467.html", "source_name": "Market source", "published_at": "2026-07-08T06:10:30", "published_display": "08 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Corporate presentation Summary", "summary": "Viking Therapeutics (VKTX) presented a summary of its corporate strategy, focusing on novel therapeutics for metabolic and endocrine diseases. Key highlights include the advanced clinical development of VK2735 for obesity, demonstrating significant weight loss in both subcutaneou", "url": "https://quartr.com/events/viking-therapeutics-vktx-corporate-presentation_on2Aof0K", "source_name": "Quartr", "published_at": "2026-07-07T22:11:21", "published_display": "07 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Q2 2024 earnings summary", "summary": "Viking Therapeutics (VKTX) reported its Q2 2024 earnings, highlighting positive phase II results for VK2735 in obesity with significant weight reduction and good tolerability. The company also detailed strong cash reserves of $942M, boosted by a public offering, and outlined upco", "url": "https://quartr.com/events/viking-therapeutics-inc-vktx-q2-2024_on2AXP69", "source_name": "Quartr", "published_at": "2026-07-07T21:10:30", "published_display": "07 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Proxy filing Summary", "summary": "Viking Therapeutics' proxy filing outlines the agenda for its annual meeting on May 19, 2026, which includes voting on the election of two Class II directors, ratification of CBIZ CPAs P.C. as independent auditors, and an advisory vote on executive compensation. Shareholders regi", "url": "https://quartr.com/events/viking-therapeutics-inc-vktx-proxy-filing_on2AFGyK", "source_name": "Quartr", "published_at": "2026-07-07T19:10:30", "published_display": "07 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Starts VK3019 Trial As Obesity Pipeline Narrative Meets Valuation", "summary": "Viking Therapeutics (VKTX) has initiated a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist for weight loss, adding to its obesity pipeline which includes the late-stage candidate VK2735. The stock has seen significant momentum with a 30-day return of 36.06", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-starts-vk3019-trial-as-obesity-pipe", "source_name": "Simply Wall Street", "published_at": "2026-07-07T07:42:35", "published_display": "07 Jul 2026 07:42", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VKTX - Viking Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Viking Therapeutics Inc (VKTX), including its last closing price, market capitalization, key financial ratios, and performance metrics. It also lists insider ownership and transactions, institutional ownership, and short inte", "url": "https://finviz.com/stock?t=VKTX&ta=1&p=w&ty=oc&r=y2&ov=list_strike&s=24.5", "source_name": "Finviz", "published_at": "2026-07-03T01:40:22", "published_display": "03 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Viking Therapeutics Stock Going to $100?", "summary": "Viking Therapeutics is a clinical-stage biotech company with promising weight-loss drug candidates, particularly VK2735, which mimics GLP-1 and GIP hormones. The company is undergoing Phase 3 trials for VK2735 and developing an oral formulation, with potential for its stock to re", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/3083854/is-viking-therapeutics-stock-going-to-100/", "source_name": "The Globe and Mail", "published_at": "2026-07-01T18:40:34", "published_display": "01 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viking Therapeutics (VKTX) Is Up 22.2% After Advancing VK3019 Into First-in-Human Obesity Trial", "summary": "Viking Therapeutics' stock rose 22.2% after it advanced VK3019, a new obesity treatment, into a Phase 1 clinical trial following FDA clearance. This move expands Viking's metabolic disease pipeline, complementing its late-stage VK2735 program and aiming to build a diverse obesity", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/why-viking-therapeutics-vktx-is-up-222-after-advancing-vk301", "source_name": "Simply Wall Street", "published_at": "2026-06-30T17:09:50", "published_display": "30 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Starts A Phase 1 Obesity Trial, Is The Upside Already Priced In?", "summary": "Viking Therapeutics (VKTX) has commenced a Phase 1 trial for VK3019, its new dual amylin and calcitonin receptor agonist targeting obesity, sparking investor interest as the stock has already seen significant gains. Despite a strong market run with shares up over 5x in five years", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-starts-a-phase-1-obesity-trial-is-t", "source_name": "Simply Wall Street", "published_at": "2026-06-29T13:41:04", "published_display": "29 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Viking Therapeutics, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Viking Therapeutics, Inc. The ETFs are sorted by their market value dedicated to Viking Therapeutics, Inc. and include details like the ETF's issuer, management style, focus, expense ratio, assets under m", "url": "https://www.tradingview.com/symbols/LSE-0VQA/etfs/", "source_name": "TradingView", "published_at": "2026-06-29T02:39:30", "published_display": "29 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Viking Therapeutics, Inc. \u2013 NASDAQ:VKTX", "summary": "This article focuses on the enterprise value to EBITDA forward for Viking Therapeutics, Inc. (NASDAQ: VKTX) as observed on TradingView. It appears to be a stub or a section of a larger financial data presentation, providing a specific financial metric for the company. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-VKTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:04", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Viking Therapeutics, Inc. \u2013 NASDAQ:VKTX", "summary": "The article focuses on the enterprise value to EBIT forward for Viking Therapeutics, Inc. (NASDAQ: VKTX) and provides financial data for the company. It serves as a financial information page on TradingView, listing various related metrics and offering general market data without", "url": "https://www.tradingview.com/symbols/NASDAQ-VKTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:39:20", "published_display": "27 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1", "summary": "Viking Therapeutics has initiated a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist, broadening its obesity treatment pipeline. This new candidate could complement existing GLP-1 therapies like VK2735, which is currently in Phase 3 trials for both subcutan", "url": "https://www.streetwisereports.com/article/2026/06/27/viking-therapeutics-expands-obesity-pipeline-with-vk3019-phase-1.html", "source_name": "Streetwise Reports", "published_at": "2026-06-27T09:39:20", "published_display": "27 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTERYLUo0Zjd3UXRXaC1kdHdPZ0Z5Q1o5RTFYd0dTX25lQWV1dElQTzBXYWxCblZERGpobjRCd3c4SjJDZHFrVmRLeUl6WDVKaWxZR20tWTJGU3Nxd0hvTXZKVGUzYjRrNTd4NEUwVm5UWTh5NW9ESEM0SDRrTDJELWthcEk1NVdEZXh0V2NiMFYyT2w2cnA4M0lBU0t4Ukk?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics stock (US92686J1060): Q1 2026 loss and volatile Nasdaq trading in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPQnNRRWszOVVIZXEzOXdTcWlUX2NkbnJ5b2hJMnBNb3BqdGF4ZXRPemRmQW4tQWoxX3NDSmxBck1IdUdHWXdpeTd2bTBQQkRqZ01HMF9mbWdFRFRKQUFFSzJ1ZEgyVFhzVk9jRkQ0QWZHOXFqRjRab0VWOThPVlJsZzVLNzZtX3lDalhuVmp5QjBWdDlVMU1wUXNJZTVsR0IzbnoyZE9LZzVtS05JQzlMcmRSRFlWbVkzcnU3WWIzV015djVROElJX3Rn?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vanguard holds 5.88M Viking Therapeutics shares (NASDAQ: VKTX) in 13G", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMi1yX0x4U19WcWhPM2JQaGF1SjNMMVZKdlduMzhLSWlMRmdJaF9pS0cwbmhaVnBPcUtjVFRYOTNCQ1RLb09sWklBSzY5LTRMb1VWaUJMMXA2MzViV2pwM0Y4ZEg4eU54TGRUT0pNZU9FblpIZGhTaTJmcWd5OUVSR2tURlM0NnVDU1NBaUh5ZmtqVEYyR1NNRlVoS1NjYm1YaTZHWnlKdl9HbHkxOXBrS2ItbXBsQllRVlFFY29yeEFPMjV1Q1pER0tn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vanguard disaggregates holdings; reports 0 shares in Viking (VKTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPaGMwNnZUSDVZSnhBSnA4b0VoUFlDUmlJZF9aUlBya1g5TDUteUlUU2ltTkFDbV9PUExmeG5uRDVhSDV2UHFsZHdzWEtVbTBDb0dsNURUcDBSa0ZDU2RYRDViQnNWXzA4a3AtLThCVHppUWh3WTk5Ukd2ZGNOOVBtWTF2TzdUcm5VQmFoT1VnYUNWVnBMR1dzYlViMFhvaE9ueTNCWmVncEIwOGlOVFFNbjlCSVAtUjdpVFlvVHp0ZG9NVTh1X1k2U1RNRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Stock Forecast 2026\u20132030 | Future Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPRVRubHhjdklTUTdfOHBQTWNZeVd5czVXM1Q4TVMzbW45ckcxUFZsU1lQbmh3U05sWkdnUDZMSzZVZDU0UHR0QThJVUJHdEhxQ1otUWw3bFdTckhmei1wZ2pTNFY5TG5saUJOOS16dzNSME8zVGlGYTJ2bFhrQjI3V1loT2pOeVVlUEFfUjFIZE8?oc=5", "source_name": "Capital.com", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZGZOYlVaMFhhVDV5SzA0dTAzT1FoMEFfN29wV3FTNGJBUGZmMl9Fejlyb29ZVnNzZ2xfS3l1S2lBcWFESndxNzMtRHhYX2F3d19NMFNrcmZ3dWRfeTJJVDdqdDVlUnlsNGV5VVpmR2VfLWs2TkNYa0RoaUwycE92V19QVVJEaFRKM29nc3lhTEFWaVJSNm5iZElFdVgzNzVTNWdPMFNOTHpkSmg1WHh2MFhkUkFRbGtEem8tcQ?oc=5", "source_name": "TradingView", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxORjluSzctams2VVZFbVJDTmtyMkNwZURmRzd6cGsxeFVPSDdibTVhM25UWXcyTnFJXzZkN2VqQ3VtWDZwRnR2NmNUUlZBNnd3ZjVfekJfQnJZYnR1V25lRGF6SnI5MU5GVVVaUDZ4RF9pS1ZoZG5MY1VOZ19rUEFRVDFYOFRqbEVBck1SRHBuYkpURTV6bzBaMmhKZzJJSmlmT3dMczM4cWMtNC12VzB5aDgtWktBRWRfQ3hfMzV0SEpxY2t1NW40ZjkwV2RIQU1rMXBBZVRKLWZLUGdOSnRudVVmWU43RjM3U2pTNFo1ZjFmXzk2elB3ZDFscmdBUWJFaTV4dFpyMA?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Could Be Pharma\u2019s Next Big Buyout Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNY3lzYUN0MEtYZzY5ckRjZTk4M0tIWnZKeW0zWEdpV05tbnVKVU5UVXZ5RGdQWUVGN2RVekV3akNSQ2FoR2tacmlmRTZjVjlobl85cDJkT2o2blBUdHZwR3Vpei15THFPQWZkMDlILWY3RXhsb3pQalJrVUphS3VaQnVCeDFyZWxva0ItUkJXbEJYdlZmWXkxdUdVcTJaVVdReVJqWUF3?oc=5", "source_name": "24/7 Wall St.", "published_at": "2025-11-03T08:00:00+00:00", "published_display": "03 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026", "summary": "Viking Therapeutics, Inc. (NASDAQ: VKTX) announced it will release its second-quarter 2026 financial results after the market closes on Wednesday, July 29, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and provide", "url": "https://au.finance.yahoo.com/news/viking-therapeutics-report-financial-results-200500197.html", "source_name": "Market source", "published_at": "2026-07-22T20:10:58", "published_display": "22 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics\u2019 Q2 results arrive after markets close", "summary": "Viking Therapeutics (NASDAQ: VKTX) is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will also host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and provide corporate", "url": "https://www.stocktitan.net/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-d0empr90iawt.html", "source_name": "Stock Titan", "published_at": "2026-07-22T20:10:58", "published_display": "22 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYmtFNjdGWXBNbkxfbGpBYW53RXhvSlRkb3FoVG5KazFjWEY4RWZuMjVtYWtWWjdmTmNhSHBrSGZmTi01S3R1QWVOWmU3Y2xuVk52bEtJSDZiWlQ2TXFBYy1qRlhJV3JScmtaMzR6aldMbXdGdmNMdEVfTmNTVkx6ZGJQeEZ3c2JwV1llVTEzb2lBOHpwUkFXczZ6RFh3ZW5JeTdaMUVmajIyWHhCbmlnRmQxbmFqdGljOWlVTDN5aE85RlE2b0o3Nw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-22T12:02:35+00:00", "published_display": "22 Jul 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term VKTX stockholders to contact them for a free and no-obliga", "url": "https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-viking-therapeutics-inc-to-contact-law-firm-302831251.html", "source_name": "PR Newswire", "published_at": "2026-07-21T20:40:19", "published_display": "21 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1", "summary": "", "url": "https://finance.yahoo.com/m/3ee1a5bf-2109-3c8d-86ea-ce77ff0c9422/watch-out%2C-eli-lilly-and-novo.html", "source_name": "Motley Fool", "published_at": "2026-07-18T20:05:00+00:00", "published_display": "18 Jul 2026 20:05", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOUEJPM1dEMWYyR2ZtU2ViMThySUUwdFc3ZFNkWUE5NDBlR0ZWUXluREFpeEJvbVptc0NldWkzbWhRLTVMMmc0dnJzbVBYWFJmU3A1dnp5TWdveHJWMG9sQUJUNTZRMXNRRUk2N05CYVRKQU45WFM3UTNaSm5NaWdDVkpUODZqVjg0dUNVY1huR3Z3VEpkZmR3ZjlsTmRsZGd6VzZGSDdhblhUbTQzOVdpRzdLelk?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-18T17:04:16+00:00", "published_display": "18 Jul 2026 17:04", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming \"Yes.\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNcGp3YnNOREN0LXZQdXY3VXFMeDZwQ19NRVNZandoSWo5RnZya0hHN214QkVyaXgzUEtqcmJEVXQtaG1RRWsyM1owSzA5V0lDYW9rUUt5c1liYWVyd1Y2UEg3dUw5a3hhdUE3VzFwTklaNm5ZNDJpb0E1dDZRNGt5MDVabnpUWDdNV2hsMUdYbXFvdk9zMWJvZGtNVXU1V1U?oc=5", "source_name": "Market source", "published_at": "2026-07-18T13:50:00+00:00", "published_display": "18 Jul 2026 13:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?", "summary": "Viking Therapeutics (VKTX) is set to report its second-quarter 2026 earnings, with investors keenly focused on pipeline updates, particularly for its lead candidate VK2735 for obesity treatment. The company has no marketed drugs, so no revenues are expected, and analysts forecast", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/3338112/viking-therapeutics-to-report-q2-earnings-whats-in-store-for-the-stock/", "source_name": "The Globe and Mail", "published_at": "2026-07-18T01:10:33", "published_display": "18 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note", "summary": "Viking Therapeutics (VKTX) stock performed strongly, gaining 1.95% while the broader market indices like the S&P 500, Dow, and Nasdaq fell. The company's stock has risen 19.72% over the past month, outperforming its sector and the S&P 500. Analysts expect Viking Therapeutics to r", "url": "https://sg.finance.yahoo.com/news/viking-therapeutics-inc-vktx-ascends-214505745.html", "source_name": "Market source", "published_at": "2026-07-17T22:09:09", "published_display": "17 Jul 2026 22:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial", "summary": "Viking Therapeutics (VKTX) has initiated a Phase 1 study for VK3019, a potential weight loss therapy. Despite recent stock fluctuations, the company shows strong long-term momentum, with Simply Wall St's analysis suggesting it is 61% undervalued compared to a fair value of $92.72", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-could-be-61-undervalued-as-it-start", "source_name": "Simply Wall Street", "published_at": "2026-07-17T20:09:09", "published_display": "17 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Law firm probes Viking Therapeutics officers for possible self-dealing harming shareholders", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties through potential self-dealing, which could result in shareholder damages. The firm is encouraging long-term shareholders to contact them for free consulta", "url": "https://pluang.com/en/news-feed/kuehn-law-ajakan-pemegang-saham-viking-therapeutics-untuk-kontak-firma-hukum", "source_name": "Pluang", "published_at": "2026-07-17T01:40:46", "published_display": "17 Jul 2026 01:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQZTRaelZOYV9TaDhlai1IX0VsWE1ZNEc5NHo5RkJRSnFCVmJ1TTlONXJsY3pSYkI5SjR3eWhDVUJ6TXdvdUVSRUlSdng3cDdxWW11ZExSbGZUU0JjME1RMWZYTlQ4QmhlR2d0ZFE4eDljOVEzWG5FRjVoRzA1WmNOX3BXeE1ESFN2R3BVNkUzY3dBR2hMUkpKcUpTNzRqUU9V?oc=5", "source_name": "Market source", "published_at": "2026-07-16T21:50:04+00:00", "published_display": "16 Jul 2026 21:50", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Is Why Viking Therapeutics (VKTX) is Amongst The Most Affordable Biotech Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNd1FSMHQyaXBELUNScW1CVlR3LXlKNERyOTRkaWNUREZTekY2S3ZUY2lrNTJBVXlacWE4LUtkYUlPUHEtVVZfYW9kWFdTTjFvdExyUzdyaE01eTY2X2V5RmZUQjZwUEJ4dnZMc0lzOHFDZ2pTWFdoMjQ0Q2ZpVFZCY1kwNWcwemF4ZktJQTVLOU02ZGtEb09jVWxpa2w4dw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:42+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival", "summary": "Viking Therapeutics' new obesity drug candidate, VK3019, demonstrated stronger early weight-loss signals in animal studies compared to Novo Nordisk's amylin therapy, although VKTX stock dipped slightly after the announcement. The company plans to begin Phase 1 testing for VK3019 ", "url": "https://stocktwits.com/news-articles/markets/equity/vktx-stock-slips-premarket-obesity-drug-beats-novo-animal-tests/cZBM2E4Re4b", "source_name": "Stocktwits", "published_at": "2026-07-11T04:43:25", "published_display": "11 Jul 2026 04:43", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "Viking Therapeutics (VKTX) stock fell 5.54% in the latest trading session, underperforming the broader market which saw gains. Despite this dip, the company's shares have increased significantly over the last month. Investors are anticipating VKTX's upcoming financial results, wi", "url": "https://ca.finance.yahoo.com/news/viking-therapeutics-inc-vktx-stock-214503928.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-10T21:40:16", "published_display": "10 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years", "summary": "Viking Therapeutics (NASDAQ: VKTX) has significantly outperformed the market over the last decade, with an annualized return of 40.15%. An initial investment of $1000 in VKTX stock ten years ago would now be worth $29,903.10. This impressive performance highlights the power of co", "url": "https://www.benzinga.com/news/26/07/60392425/here-s-how-much-you-would-have-made-owning-viking-therapeutics-stock-last-10-years", "source_name": "Benzinga", "published_at": "2026-07-10T16:39:19", "published_display": "10 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength", "summary": "Viking Therapeutics (VKTX) is showing signs of a long-term bottoming pattern, with improving technical indicators suggesting a potential breakout. Key resistance is at $43.15, and recent advances with increased volume signal strengthening demand. While a pullback could precede a ", "url": "https://www.fxempire.com/forecasts/article/viking-therapeutics-vktx-price-forecast-bottoming-pattern-signals-growing-strength-1609462", "source_name": "FXEmpire", "published_at": "2026-07-09T21:33:57", "published_display": "09 Jul 2026 21:33", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?", "summary": "Viking Therapeutics has expanded its obesity drug pipeline by initiating a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist, alongside its existing GLP-1/GIP program. While VK3019 broadens the company's multi-mechanism approach to obesity treatment, the nea", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/does-viking-therapeutics-vktx-expanding-into-dual-agonist-ob", "source_name": "Simply Wall Street", "published_at": "2026-07-09T21:03:57", "published_display": "09 Jul 2026 21:03", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?", "summary": "Viking Therapeutics (VKTX) is increasingly seen as a potential acquisition target due to its expanding obesity franchise, particularly with its lead candidate VK2735 and the addition of VK3019. The company is poised for a significant catalyst with upcoming data readouts from a ma", "url": "https://www.tradingview.com/news/zacks:6d7d003ca094b:0-buyout-buzz-around-vktx-is-back-what-s-fueling-the-speculation/", "source_name": "TradingView", "published_at": "2026-07-09T14:03:57", "published_display": "09 Jul 2026 14:03", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Jefferies Global Healthcare Conference 2026 Summary", "summary": "This summary from the Jefferies Global Healthcare Conference 2026 details Viking Therapeutics' progress, including two Phase III trials for obesity (VANQUISH-1 and VANQUISH-2) nearing data release in late 2027, and the impending launch of two Phase III trials for an oral GLP-1/GI", "url": "https://quartr.com/events/viking-therapeutics-vktx-jefferies-global-healthcare-conference-2026_on2AF4xJ", "source_name": "Quartr", "published_at": "2026-07-08T22:43:25", "published_display": "08 Jul 2026 22:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Stock Looks Pricey After New Obesity Trial Launch", "summary": "Viking Therapeutics' stock appears expensive due to a high P/B ratio compared to industry averages, despite a strong five-year return. The launch of its Phase 1 obesity trial for VK3019 supports a broader pipeline, but clinical and regulatory risks persist. The company's valuatio", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-stock-looks-pricey-after-new-obesit/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T11:39:53", "published_display": "08 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPczZPMWFhaHU3Q3FaMGxMWU5HVGxlV3d1eDNmYklhMWpfdWJId00wbnBJR0lwS2F0VkxYb1Bod1hUMDh0MEVjRURrVmF3NWE0cGVZY1pEbElaV0VZU0Z4dWg1R1VUZ3dtanNPRDBJQTZ2UjJpSXlMOUw2WXRBUzBGbjRIMWJUbk1SMnkydnBoNEI0eEZ2UlJFRWhBRG5kTC1kY0dJ?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Could Be 120% Undervalued On Obesity Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxONTg2c2xDWm1HeThZZ1dTamRXbGNSZ3NRMm94X1hQcVB5RkMzV0l2bHJDcldCS1AtX0t0ZHNBSTBVb2ZVa0hYZXcxU2J4Y3FiQTNqeHNtR202bThPU0JwcTdwb2YyRFUxTjRjSmMyVnZjQ3hvMUFpYVBRY0NfNHE2bXhuVmVIVXBfYml4RkNPdWZPT3k4czY1OXF6SQ?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 \u2013 And What's Next", "summary": "Viking Therapeutics has initiated a Phase 1 trial for its new obesity drug VK3019, a dual amylin and calcitonin receptor agonist, broadening its metabolic pipeline alongside its advanced VK2735 program. This development could reshape Viking's investment narrative by adding anothe", "url": "https://finance.yahoo.com/healthcare/articles/why-viking-therapeutics-vktx-8-061220467.html", "source_name": "Market source", "published_at": "2026-07-08T06:10:30", "published_display": "08 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Corporate presentation Summary", "summary": "Viking Therapeutics (VKTX) presented a summary of its corporate strategy, focusing on novel therapeutics for metabolic and endocrine diseases. Key highlights include the advanced clinical development of VK2735 for obesity, demonstrating significant weight loss in both subcutaneou", "url": "https://quartr.com/events/viking-therapeutics-vktx-corporate-presentation_on2Aof0K", "source_name": "Quartr", "published_at": "2026-07-07T22:11:21", "published_display": "07 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Q2 2024 earnings summary", "summary": "Viking Therapeutics (VKTX) reported its Q2 2024 earnings, highlighting positive phase II results for VK2735 in obesity with significant weight reduction and good tolerability. The company also detailed strong cash reserves of $942M, boosted by a public offering, and outlined upco", "url": "https://quartr.com/events/viking-therapeutics-inc-vktx-q2-2024_on2AXP69", "source_name": "Quartr", "published_at": "2026-07-07T21:10:30", "published_display": "07 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Proxy filing Summary", "summary": "Viking Therapeutics' proxy filing outlines the agenda for its annual meeting on May 19, 2026, which includes voting on the election of two Class II directors, ratification of CBIZ CPAs P.C. as independent auditors, and an advisory vote on executive compensation. Shareholders regi", "url": "https://quartr.com/events/viking-therapeutics-inc-vktx-proxy-filing_on2AFGyK", "source_name": "Quartr", "published_at": "2026-07-07T19:10:30", "published_display": "07 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Starts VK3019 Trial As Obesity Pipeline Narrative Meets Valuation", "summary": "Viking Therapeutics (VKTX) has initiated a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist for weight loss, adding to its obesity pipeline which includes the late-stage candidate VK2735. The stock has seen significant momentum with a 30-day return of 36.06", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-starts-vk3019-trial-as-obesity-pipe", "source_name": "Simply Wall Street", "published_at": "2026-07-07T07:42:35", "published_display": "07 Jul 2026 07:42", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VKTX - Viking Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Viking Therapeutics Inc (VKTX), including its last closing price, market capitalization, key financial ratios, and performance metrics. It also lists insider ownership and transactions, institutional ownership, and short inte", "url": "https://finviz.com/stock?t=VKTX&ta=1&p=w&ty=oc&r=y2&ov=list_strike&s=24.5", "source_name": "Finviz", "published_at": "2026-07-03T01:40:22", "published_display": "03 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Viking Therapeutics Stock Going to $100?", "summary": "Viking Therapeutics is a clinical-stage biotech company with promising weight-loss drug candidates, particularly VK2735, which mimics GLP-1 and GIP hormones. The company is undergoing Phase 3 trials for VK2735 and developing an oral formulation, with potential for its stock to re", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/3083854/is-viking-therapeutics-stock-going-to-100/", "source_name": "The Globe and Mail", "published_at": "2026-07-01T18:40:34", "published_display": "01 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viking Therapeutics (VKTX) Is Up 22.2% After Advancing VK3019 Into First-in-Human Obesity Trial", "summary": "Viking Therapeutics' stock rose 22.2% after it advanced VK3019, a new obesity treatment, into a Phase 1 clinical trial following FDA clearance. This move expands Viking's metabolic disease pipeline, complementing its late-stage VK2735 program and aiming to build a diverse obesity", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/why-viking-therapeutics-vktx-is-up-222-after-advancing-vk301", "source_name": "Simply Wall Street", "published_at": "2026-06-30T17:09:50", "published_display": "30 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Starts A Phase 1 Obesity Trial, Is The Upside Already Priced In?", "summary": "Viking Therapeutics (VKTX) has commenced a Phase 1 trial for VK3019, its new dual amylin and calcitonin receptor agonist targeting obesity, sparking investor interest as the stock has already seen significant gains. Despite a strong market run with shares up over 5x in five years", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-starts-a-phase-1-obesity-trial-is-t", "source_name": "Simply Wall Street", "published_at": "2026-06-29T13:41:04", "published_display": "29 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Viking Therapeutics, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Viking Therapeutics, Inc. The ETFs are sorted by their market value dedicated to Viking Therapeutics, Inc. and include details like the ETF's issuer, management style, focus, expense ratio, assets under m", "url": "https://www.tradingview.com/symbols/LSE-0VQA/etfs/", "source_name": "TradingView", "published_at": "2026-06-29T02:39:30", "published_display": "29 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Viking Therapeutics, Inc. \u2013 NASDAQ:VKTX", "summary": "This article focuses on the enterprise value to EBITDA forward for Viking Therapeutics, Inc. (NASDAQ: VKTX) as observed on TradingView. It appears to be a stub or a section of a larger financial data presentation, providing a specific financial metric for the company. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-VKTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:04", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Viking Therapeutics, Inc. \u2013 NASDAQ:VKTX", "summary": "The article focuses on the enterprise value to EBIT forward for Viking Therapeutics, Inc. (NASDAQ: VKTX) and provides financial data for the company. It serves as a financial information page on TradingView, listing various related metrics and offering general market data without", "url": "https://www.tradingview.com/symbols/NASDAQ-VKTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:39:20", "published_display": "27 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1", "summary": "Viking Therapeutics has initiated a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist, broadening its obesity treatment pipeline. This new candidate could complement existing GLP-1 therapies like VK2735, which is currently in Phase 3 trials for both subcutan", "url": "https://www.streetwisereports.com/article/2026/06/27/viking-therapeutics-expands-obesity-pipeline-with-vk3019-phase-1.html", "source_name": "Streetwise Reports", "published_at": "2026-06-27T09:39:20", "published_display": "27 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTERYLUo0Zjd3UXRXaC1kdHdPZ0Z5Q1o5RTFYd0dTX25lQWV1dElQTzBXYWxCblZERGpobjRCd3c4SjJDZHFrVmRLeUl6WDVKaWxZR20tWTJGU3Nxd0hvTXZKVGUzYjRrNTd4NEUwVm5UWTh5NW9ESEM0SDRrTDJELWthcEk1NVdEZXh0V2NiMFYyT2w2cnA4M0lBU0t4Ukk?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics stock (US92686J1060): Q1 2026 loss and volatile Nasdaq trading in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPQnNRRWszOVVIZXEzOXdTcWlUX2NkbnJ5b2hJMnBNb3BqdGF4ZXRPemRmQW4tQWoxX3NDSmxBck1IdUdHWXdpeTd2bTBQQkRqZ01HMF9mbWdFRFRKQUFFSzJ1ZEgyVFhzVk9jRkQ0QWZHOXFqRjRab0VWOThPVlJsZzVLNzZtX3lDalhuVmp5QjBWdDlVMU1wUXNJZTVsR0IzbnoyZE9LZzVtS05JQzlMcmRSRFlWbVkzcnU3WWIzV015djVROElJX3Rn?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard holds 5.88M Viking Therapeutics shares (NASDAQ: VKTX) in 13G", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMi1yX0x4U19WcWhPM2JQaGF1SjNMMVZKdlduMzhLSWlMRmdJaF9pS0cwbmhaVnBPcUtjVFRYOTNCQ1RLb09sWklBSzY5LTRMb1VWaUJMMXA2MzViV2pwM0Y4ZEg4eU54TGRUT0pNZU9FblpIZGhTaTJmcWd5OUVSR2tURlM0NnVDU1NBaUh5ZmtqVEYyR1NNRlVoS1NjYm1YaTZHWnlKdl9HbHkxOXBrS2ItbXBsQllRVlFFY29yeEFPMjV1Q1pER0tn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard disaggregates holdings; reports 0 shares in Viking (VKTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPaGMwNnZUSDVZSnhBSnA4b0VoUFlDUmlJZF9aUlBya1g5TDUteUlUU2ltTkFDbV9PUExmeG5uRDVhSDV2UHFsZHdzWEtVbTBDb0dsNURUcDBSa0ZDU2RYRDViQnNWXzA4a3AtLThCVHppUWh3WTk5Ukd2ZGNOOVBtWTF2TzdUcm5VQmFoT1VnYUNWVnBMR1dzYlViMFhvaE9ueTNCWmVncEIwOGlOVFFNbjlCSVAtUjdpVFlvVHp0ZG9NVTh1X1k2U1RNRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Stock Forecast 2026\u20132030 | Future Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPRVRubHhjdklTUTdfOHBQTWNZeVd5czVXM1Q4TVMzbW45ckcxUFZsU1lQbmh3U05sWkdnUDZMSzZVZDU0UHR0QThJVUJHdEhxQ1otUWw3bFdTckhmei1wZ2pTNFY5TG5saUJOOS16dzNSME8zVGlGYTJ2bFhrQjI3V1loT2pOeVVlUEFfUjFIZE8?oc=5", "source_name": "Capital.com", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZGZOYlVaMFhhVDV5SzA0dTAzT1FoMEFfN29wV3FTNGJBUGZmMl9Fejlyb29ZVnNzZ2xfS3l1S2lBcWFESndxNzMtRHhYX2F3d19NMFNrcmZ3dWRfeTJJVDdqdDVlUnlsNGV5VVpmR2VfLWs2TkNYa0RoaUwycE92V19QVVJEaFRKM29nc3lhTEFWaVJSNm5iZElFdVgzNzVTNWdPMFNOTHpkSmg1WHh2MFhkUkFRbGtEem8tcQ?oc=5", "source_name": "TradingView", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxORjluSzctams2VVZFbVJDTmtyMkNwZURmRzd6cGsxeFVPSDdibTVhM25UWXcyTnFJXzZkN2VqQ3VtWDZwRnR2NmNUUlZBNnd3ZjVfekJfQnJZYnR1V25lRGF6SnI5MU5GVVVaUDZ4RF9pS1ZoZG5MY1VOZ19rUEFRVDFYOFRqbEVBck1SRHBuYkpURTV6bzBaMmhKZzJJSmlmT3dMczM4cWMtNC12VzB5aDgtWktBRWRfQ3hfMzV0SEpxY2t1NW40ZjkwV2RIQU1rMXBBZVRKLWZLUGdOSnRudVVmWU43RjM3U2pTNFo1ZjFmXzk2elB3ZDFscmdBUWJFaTV4dFpyMA?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics Could Be Pharma\u2019s Next Big Buyout Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNY3lzYUN0MEtYZzY5ckRjZTk4M0tIWnZKeW0zWEdpV05tbnVKVU5UVXZ5RGdQWUVGN2RVekV3akNSQ2FoR2tacmlmRTZjVjlobl85cDJkT2o2blBUdHZwR3Vpei15THFPQWZkMDlILWY3RXhsb3pQalJrVUphS3VaQnVCeDFyZWxva0ItUkJXbEJYdlZmWXkxdUdVcTJaVVdReVJqWUF3?oc=5", "source_name": "24/7 Wall St.", "published_at": "2025-11-03T08:00:00+00:00", "published_display": "03 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 54, "sentiment_summary": {"positive": 19, "negative": 9, "neutral": 26, "score": 55, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 18.15, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 37.08, "latest_week": "2026-07-17", "one_week_move": -4.6, "four_week_move": 22.1, "twelve_week_move": 13.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.084652, "market_dynamics_buy_signal": false, "relative_strength": 0.834784, "fair_value_gap": -0.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.2062, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.6% over one week, +22.1% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "Simply Wall Street", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Quartr", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "Stocktwits", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 14}, {"label": "Guidance", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.6% over one week, +22.1% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026"}], "updated_at": "2026-07-23T07:09:01.484131+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}